| For: | Li YP, Liu CR, He L, Dang SS. Hepatitis B cure: Current situation and prospects. World J Hepatol 2024; 16(6): 900-911 [PMID: 38948438 DOI: 10.4254/wjh.v16.i6.900] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v16/i6/900.htm |
| Number | Citing Articles |
| 1 |
Shuchang Shang, Yuexia Liu, Caiyan Zhao. Case Report: Unexpected HBV reactivation upon nucleos(t)ide analogue discontinuation despite 17 years of sustained HBsAg loss post-liver transplantation. Frontiers in Medicine 2026; 13 doi: 10.3389/fmed.2026.1954979
|
| 2 |
Mei Li, Dandan Feng, Juanjuan Shi, Shuangsuo Dang, Xiaoli Jia, Wenjun Wang. PD-1/PD-L1 blockade as part of combination strategies toward functional cure of chronic hepatitis B. Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1831739
|
| 3 |
Soe Thiha Maung, Roongruedee Chaiteerakij. Scoping Review on Strategies for Safe Nucleot(s)ide Analogue Discontinuation and Optimising Functional Cure in Chronic Hepatitis B. Journal of Viral Hepatitis 2025; 32(7) doi: 10.1111/jvh.70040
|
| 4 |
Li-li Liu, Yi Feng, Chao-yi Ren, Yi Liu, Ming-hui Zhu, Guo-xiang Hao, Tian-tian Gao. A Real-World Pharmacological Assessment of Tenofovir Amibufenamide and Tenofovir Alafenamide in 48-Week Chronic Hepatitis B Treatment: Efficacy, Safety, and Cost-Effectiveness. Current Medical Science 2025; 45(5) doi: 10.1007/s11596-025-00120-5
|